new data findings/day
patient tests analyzed
Real time access and analysis of over 40 genomic and clinical databases covering over 33,000 diseases.
Join us at an event or attend a webinar to learn how our products, solutions and services are empowering customers around the world to unlock valuable molecular insights.
Evidence based research, services and advanced software for better decisions.
The Winter 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expand...
Read about how researchers across the world are using QIAGEN Digital Insights solutions to accelerat...
Discover more about the latest QCI features and how the platform simplifies and accelerates NGS vari...
Check out the new features of QIAGEN CLC Genomics Are you struggling to find a bioinformatics a...
We are excited to announce the general availability of the Fall 2020 Release of QIAGEN Clinical Insi...
HGMD Professional 2020.4 Release
QIAGEN Digital Insights Publication Roundup (Winter 2020/2021)
What's New in QIAGEN Clinical Insights (QCI)?
Learn what's new in the QIAGEN CLC Genomics version 21 (v21) release
New Features and Functionalities of QCI Interpret
Targeted NGS panels and optimized analysis and interpretation tools.
Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics services that ensure high-quality results.
Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.
Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.
QIAGEN maintains the world’s largest, expert-curated knowledgebase of up-to-date evidence for discovery research, clinical test interpretation and pharmaceutical development.
Interpretation of gene expression data to tackle inflammatory bowel disease
In Germany, scientists tackle cancer cohorts with Sample to Insight QIAGEN tools.
Mount Sinai's novel biomarker predicts treatment outcome in ovarian cancer